Drug Type Small molecule drug |
Synonyms Ossirene, AS 101, AS101 + [7] |
Target |
Mechanism α4β1 antagonists(Integrin alpha-4/beta-1 antagonists), αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC2H8Cl3NO2Te |
InChIKeyAXWLPMGUUAIGJK-UHFFFAOYSA-O |
CAS Registry106566-58-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet Macular Degeneration | Phase 2 | IL | 29 Oct 2018 | |
Dystrophy, Macular | Phase 2 | IL | 08 Oct 2018 | |
Acute Myeloid Leukemia | Phase 2 | IL | 01 Jan 2015 | |
Myelodysplastic Syndromes | Phase 2 | IL | 01 Jan 2015 | |
Condylomata Acuminata | Phase 2 | IL | 14 Mar 2012 | |
Warts | Phase 2 | IL | 01 Mar 2012 | |
Solid tumor | Phase 2 | IL | 01 Aug 2009 | |
Thrombocytopenia | Phase 2 | IL | 01 Aug 2009 | |
Dermatitis, Atopic | Phase 2 | IL | 01 Jun 2009 | |
Psoriasis | Phase 2 | IL | 01 Nov 2008 |